ArticlePharmacoEconomics - open2026
Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A.
Li Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.